Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropiclobet for Sciatic Nerve Block in Healthy Volunteers
NCT06781632Phase 1Completed
- Sponsor
- Pharmafina
- Start
- Nov 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ropivacaine + betamethasone + clonidine in pain, sponsored by Pharmafina. Primary endpoints: Number of treatment-related adverse events assessed by NCI-CTCAE, Number of treatment-related adverse events assessed by laboratory parameters at Day 30 and 2 more. Started Nov 2024; status: completed.
02
Drugs
ropivacaine + betamethasone + clonidine
03
Conditions
pain
Beyond the preview
Go deeper on NCT06781632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06781632.